GENETICS OF ANTIEPILEPTIC MEDICATION METABOLISM

正在寻求癫痫患者的知情同意， 以缓慢速率代谢AED（组1），以平均速率代谢AED（格鲁（2）， 和慢代谢者的家庭成员（第3组）。 患者（组 1）、对照组（组2）和家庭成员（组3）将被带到 稳定状态与AED，他们通常采取（组1和2）或与 第1组的家庭成员正在服用低剂量的AED （第3组）。 参加者将被要求向CRC报告， 明尼苏达大学，他们将被录取约24小时。 相同的剂量方案（q12）将在患者的整个治疗期间持续。 留在CRC。 一个小的留置导管将被插入一个 静脉在病人的前臂，使多个血液样本可以 很方便地拿走了。 患者将被要求收集他们的尿液到一个 容器在24小时内开始之前采取的 血液样本 将对血液和尿液标本进行血液分析 化学（以评估肝功能，肾功能，以及 蛋白结合）用于肌酐清除率（评估肾功能），以及 母体药物和代谢物浓度（以评估 特定代谢途径对AED代谢的贡献）。

Informed consent are being sought from patients with epilepsy that metabolize AEDs at a slow rate (Group 1), at an average rate (Grou( 2), and family members of the slow metabolizers (Group 3). Patients (Group 1), controls (Group 2), and family members (Group 3) will be brought to steady state with the AED that they normally take (Groups 1 and 2) or with a low dose of the AED that their family member from Group 1 is taking (Group 3). Participants will be asked to report to the CRC at the University of MN where they will be admitted for approximately 24 hours. The same dosage regimen (q12) will be continued throughout the patients' stay at the CRC. A small indwelling catheter will be inserted into a vein in the patient's forearm so that multiple blood samples can be conveniently taken. Patients will be asked to collect their urine into a container over a 24 hour period beginning just prior to the taking of the blood sample. Blood and urine specimens will be analyzed for blood chemistries (to assess liver function, kidney function, and the amount of protein binding) for creatinine clearance (to assess kidney function) and for the parent drug and metabolite concentrations (to assess the contribution of specific metabolic pathways to AED metabolism).